Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1165/rcmb.2020-0188TR http://scihub22266oqcxt.onion/10.1165/rcmb.2020-0188TR 32640172!7605157!32640172     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Am+J+Respir+Cell+Mol+Biol 2020 ; 63 (5): 571-590 Nephropedia Template TP {{tp|p=32640172|t=2020. Poly(ADP-Ribose) Polymerase Inhibition in Acute Lung Injury A Reemerging Concept |pdf=|usr=}}{{32640172}} gab.com Text Poly(ADP-Ribose) Polymerase Inhibition in Acute Lung Injury A Reemerging Concept JO: Am J Respir Cell Mol Biol http://www.kidney.de/pget.php?&tw=1&pmid=32640172 #FOAvip PARP1, the major isoform of a family of ADP-ribosylating enzymes, has been implicated in the regulation of various biological processes including DNA repair, gene transcription, and cell death. The concept that PARP1 becomes activated in acute lung injury (ALI) and that pharmacological inhibition or genetic deletion of this enzyme can provide therapeutic benefits emerged over 20 years ago. The current article provides an overview of the cellular mechanisms involved in the pathogenetic roles of PARP1 in ALI and provides an overview of the preclinical data supporting the efficacy of PARP (poly[ADP-ribose] polymerase) inhibitors. In recent years, several ultrapotent PARP inhibitors have been approved for clinical use (for the therapy of various oncological diseases): these newly-approved PARP inhibitors were recently reported to show efficacy in animal models of ALI. These observations offer the possibility of therapeutic repurposing of these inhibitors for patients with ALI. The current article lays out a potential roadmap for such repurposing efforts. In addition, the article also overviews the scientific basis of potentially applying PARP inhibitors for the experimental therapy of viral ALI, such as coronavirus disease (COVID-19)-associated ALI. Twit Text FOAVip Poly(ADP-Ribose) Polymerase Inhibition in Acute Lung Injury A Reemerging Concept ????Am J Respir Cell Mol Biol http://www.kidney.de/pget.php?&tw=1&pmid=32640172 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32640172 #FOAvip English Wikipedia <ref>{{Cite pmid|32640172}}</ref> Poly(ADP-Ribose) Polymerase Inhibition in Acute Lung Injury A Reemerging Concept #MMPMID32640172 Szabo C; Martins V; Liaudet L Am J Respir Cell Mol Biol 2020[Nov]; 63 (5): 571-590 PMID32640172show ga PARP1, the major isoform of a family of ADP-ribosylating enzymes, has been implicated in the regulation of various biological processes including DNA repair, gene transcription, and cell death. The concept that PARP1 becomes activated in acute lung injury (ALI) and that pharmacological inhibition or genetic deletion of this enzyme can provide therapeutic benefits emerged over 20 years ago. The current article provides an overview of the cellular mechanisms involved in the pathogenetic roles of PARP1 in ALI and provides an overview of the preclinical data supporting the efficacy of PARP (poly[ADP-ribose] polymerase) inhibitors. In recent years, several ultrapotent PARP inhibitors have been approved for clinical use (for the therapy of various oncological diseases): these newly-approved PARP inhibitors were recently reported to show efficacy in animal models of ALI. These observations offer the possibility of therapeutic repurposing of these inhibitors for patients with ALI. The current article lays out a potential roadmap for such repurposing efforts. In addition, the article also overviews the scientific basis of potentially applying PARP inhibitors for the experimental therapy of viral ALI, such as coronavirus disease (COVID-19)-associated ALI. |Acute Lung Injury/*drug therapy/enzymology/virology[MESH] |Animals[MESH] |Antiviral Agents/adverse effects/*therapeutic use[MESH] |Betacoronavirus/*drug effects/pathogenicity[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Coronavirus Infections/*drug therapy/enzymology/virology[MESH] |Host-Pathogen Interactions[MESH] |Humans[MESH] |Lung/*drug effects/enzymology/virology[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy/enzymology/virology[MESH] |Poly (ADP-Ribose) Polymerase-1/*antagonists & inhibitors/metabolism[MESH] |Poly(ADP-ribose) Polymerase Inhibitors/adverse effects/*therapeutic use[MESH] |SARS-CoV-2[MESH]Poly(ADP-Ribose) Polymerase Inhibition in Acute Lung Injury A Reemerg(epmc).pdf DeepDyve Pubget Overpricing